ORIGINAL PAPER
Relationship between expression of blood circulating lncRNA: LRRC75A-AS1, clinical characteristics and prognosis of chronic heart failure patients
1
Care and Treatment Facility, Cardinal Wyszynski Voivodeship Specialist Hospital, Lublin, Poland
2
Department of Cardiology, 1st Military Clinical Hospital with the Outpatient Clinic, Lublin, Poland
3
Department of Human Physiology of the Chair of Preclinical Sciences, Medical University in Lublin, Lublin, Poland
Submission date: 2023-07-18
Final revision date: 2023-08-18
Acceptance date: 2023-08-23
Publication date: 2023-09-30
Corresponding author
Tomasz Powrózek
Tomasz Powrózek PhD, Assoc. Prof. Department of Human Physiology Chair of Preclinical Sciences Medical University in Lublin 11 Radziwillowska St, 20-080 Lublin, Poland
Tomasz Powrózek PhD, Assoc. Prof. Department of Human Physiology Chair of Preclinical Sciences Medical University in Lublin 11 Radziwillowska St, 20-080 Lublin, Poland
Medical Studies 2023;39(3):215-222
KEYWORDS
TOPICS
ABSTRACT
Introduction:
A complex interplay of genetics and multiple biological mechanisms contributes not only to chronic heart failure (CHF) progression and an unfavorable prognosis, but also makes biomarker selection difficult. Discovery of novel molecular markers, such as lncRNAs, has provided a new approach to biomarker study, including for CHF.
Aim of the research:
In this study, we focused on blood circulating LRRC75A-AS1 as a novel prospective biomarker reflecting the clinical image and prognosis of CHF patients.
Material and methods:
The lncRNA expression was examined in plasma samples of 108 newly diagnosed CHF patients and correlated with clinical outcomes.
Results:
Low expression of LRRC75A-AS1 was associated with a greater inflammatory response reflected by higher plasma concentrations of C-reactive protein, interleukin-6 and tumor necrosis factor . Patients with low lncRNA expression had lower serum albumin concentration and they were more frequently classified as NYHA grade III or IV, had PASP ≥ 36 mm Hg and more often demonstrated presence of exertional dyspnea. The Cox regression model selected downexpression of LRRC75A-AS1 as an independent prognostic factor related to poor survival of CHF (HR = 2.17).
Conclusions:
Blood circulating LRRC75A-AS1 seems to be an attractive biomarker supporting clinical assessment of CHF patients. Expression of the lncRNA reflects the extent of the CHF symptoms and severity of the systemic inflammatory response, which can be useful for selection of patients with an unfavorable disease course and higher risk of death.
A complex interplay of genetics and multiple biological mechanisms contributes not only to chronic heart failure (CHF) progression and an unfavorable prognosis, but also makes biomarker selection difficult. Discovery of novel molecular markers, such as lncRNAs, has provided a new approach to biomarker study, including for CHF.
Aim of the research:
In this study, we focused on blood circulating LRRC75A-AS1 as a novel prospective biomarker reflecting the clinical image and prognosis of CHF patients.
Material and methods:
The lncRNA expression was examined in plasma samples of 108 newly diagnosed CHF patients and correlated with clinical outcomes.
Results:
Low expression of LRRC75A-AS1 was associated with a greater inflammatory response reflected by higher plasma concentrations of C-reactive protein, interleukin-6 and tumor necrosis factor . Patients with low lncRNA expression had lower serum albumin concentration and they were more frequently classified as NYHA grade III or IV, had PASP ≥ 36 mm Hg and more often demonstrated presence of exertional dyspnea. The Cox regression model selected downexpression of LRRC75A-AS1 as an independent prognostic factor related to poor survival of CHF (HR = 2.17).
Conclusions:
Blood circulating LRRC75A-AS1 seems to be an attractive biomarker supporting clinical assessment of CHF patients. Expression of the lncRNA reflects the extent of the CHF symptoms and severity of the systemic inflammatory response, which can be useful for selection of patients with an unfavorable disease course and higher risk of death.
REFERENCES (22)
1.
Ramani GV, Uber PA, Mehra MR. Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc 2010; 85: 180-195.
2.
Groenewegen A, Rutten F, Mosterd A, Hoes A. Epidemiology of heart failure. Eur J Heart Fail 2020; 22: 1342-1356.
3.
Savarese G, Lund L. Global public health burden of heart failure. Card Fail Rev 2017; 3: 7-11.
4.
Bragazzi N, Zhong W, Shu J, Much AA, Lotan D, Grupper Avishay, Younis A, Dai H. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol 2021; 28: 1682-1690.
5.
Ibrahim N, Januzzi J. Established and emerging roles of biomarkers in heart failure. Circ Res 2018; 123: 614-629.
6.
Jones NR, Hobbs FD, Taylor CJ. Prognosis following a diagnosis of heart failure and the role of primary care: a review of the literature. BJGP Open 2017; 1: bjgpopen17X101013.
7.
Nadar S, Shaikh M. Biomarkers in routine heart failure clinical care. Card Fail Rev 2019; 5: 50-56.
8.
Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev 2022; 27: 625-643.
9.
Brunner-La Rocca HP, Sanders-van Wijk S. Natriuretic peptides in chronic heart failure. Card Fail Rev 2019; 5: 44-49.
10.
Gangus T, Burckhardt B. Potential and limitations of atrial natriuretic peptide as biomarker in pediatric heart failure – a comparative review. Front Pediatr 2019; 6: 420.
11.
Nessler J, Straburzyńska-Migaj E, Windak A, Solnica B, Szmitkowski M, Paradowski M, Kaźmierczak J, Puacz E, Rozentryt P. Expert consensus on the usefulness of natriuretic peptides in heart failure. Kardiol Pol 2018; 76: 215-224.
13.
Biasucci L, Maino A, Grimaldi M, Cappannoli L, Aspromonte N. Novel biomarkers in heart failure: new insight in pathophysiology and clinical perspective. J Clin Med 2021; 10: 2771.
14.
Jiang J, Hu H, Chen Q, Zhang Y, Chen W, Huang Q, Chen X, Li J, Zhong M. Long non-coding RNA SNHG29 regulates cell senescence via p53/p21 signaling in spontaneous preterm birth. Placenta 2021; 103: 64-71.
15.
Li S, Wu D, Jia H, Zhang Z. Long non-coding RNA LRRC75A-AS1 facilitates triple negative breast cancer cell proliferation and invasion via functioning as a ceRNA to modulate BAALC. Cell Death Dis 2020; 11: 643.
16.
Huang C, Zhan JF, Cehn YX, Xu CY, Chen Y. LncRNA-SNHG29 inhibits vascular smooth muscle cell calcification by downregulating miR-200b-3p to activate the -Klotho/FGFR1/FGF23 axis. Cytokine 2020; 136: 155243.
17.
Zhang Z, Gao W, Long QQ, Zhang J, Li YF, Liu DC, Yan JJ, Yang ZJ, Wang LS. Increased plasma levels of lncRNA H19 and LIPCAR are associated with increased risk of coronary artery disease in a Chinese population. Sci Rep 2017; 7: 7491.
18.
Luo H, Wang J, Liu D, Zang S, Ma N, Zhao L, Zhang L, Zhang X, Qiao C. The lncRNA H19/miR-675 axis regulates myocardial ischemic and reperfusion injury by targeting PPAR. Mol Immunol 2019; 105: 46-54.
19.
Deng H, Ouyang W, Zhang L, Xiao X, Huang Z, Zhu W. LncRNA GASL1 is downregulated in chronic heart failure and regulates cardiomyocyte apoptosis. Cell Mol Biol Letters 2019; 24: 41.
20.
Wang Z, Gu J, Han T, Li K. High-throughput sequencing profile of laryngeal cancers: analysis of co-expression and competing endogenous RNA networks of circular RNAs, long non-coding RNAs, and messenger RNAs. Ann Transl Med 2021; 9: 483.
21.
Chen J, Lan J, Ye Z, Duan S, hu Y, Zou Y, Zhou J. Long noncoding RNA LRRC75A-AS1 inhibits cell proliferation and migration in colorectal carcinoma. Exp Biol Med (Maywood) 2019; 244: 1137-1143.
22.
Wang X, Wang H, Zhang R, Li D, Gao MQ. LRRC75A antisense lncRNA1 knockout attenuates inflammatory responses of bovine mammary epithelial cells. Int J Biol Sci 2020; 16: 251-263.
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
